Skip to content

CninMed – China Innovative Drugs Update

  • Contact Us

Author: admin

Posted in
  • China License Out

[China BD Deal 2023] Hansoh and GSK enters a 1.71 billion USD license on B7-H3 ADC HS-20093

Announced Date: 2023-12-20 (December 20, 2023) Asset Name: HS-20093 Licensor: Hansoh Pharma  (Hansoh) (China) Licensee (Buyer): … [China BD Deal 2023] Hansoh and GSK enters a 1.71 billion USD license on B7-H3 ADC HS-20093Read more

by admin•December 21, 2023September 1, 2025•0
Posted in
  • China License Out

[China BD 2023] GenFleet and Verastem enters Collaboration, Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program

Initial Announced Date: 2023-08-28 (August 28, 2025), Updated in 2023-12-18 (December 18, 2023) Asset: Three oncology … [China BD 2023] GenFleet and Verastem enters Collaboration, Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead ProgramRead more

by admin•December 19, 2023September 3, 2025•0
Posted in
  • China License Out

[China BD Deal 2023] SystImmune and BMS enters a 8.4 billion USD license on bispecific EGFRxHER3 ADC BL-B01D1

Announced Date: 2023-12-11 (December 11, 2023) Asset Name: BL-B01D1 Licensor: SystImmune Inc., (a member of Sichuan … [China BD Deal 2023] SystImmune and BMS enters a 8.4 billion USD license on bispecific EGFRxHER3 ADC BL-B01D1Read more

by admin•December 12, 2023August 29, 2025•0
Posted in
  • China License Out

[China BD 2023] Haisco and Chiesi enters a 475 million USD license on DPP1 inhibitor HSK31858

Announced Date: 2023-11-20 (November 20, 2023) Asset Name: HSK31858 Licensor: Haisco Pharmaceutical Group (China) and Licensee … [China BD 2023] Haisco and Chiesi enters a 475 million USD license on DPP1 inhibitor HSK31858Read more

by admin•November 21, 2023September 2, 2025•0
Posted in
  • China License Out

[China BD 2023] Eccogene and AstraZeneca enters a 2 billion USD license on GLP-1RA ECC5004 (AZD5004)

Announced Date: 2023-11-09 (November 9, 2023) Asset Name: ECC5004(AZD5004) Licensor: Eccogene (China) Licensee (Buyer): AstraZeneca(UK) . … [China BD 2023] Eccogene and AstraZeneca enters a 2 billion USD license on GLP-1RA ECC5004 (AZD5004)Read more

by admin•November 10, 2023September 3, 2025•0
Posted in
  • China License Out

[China BD 2023] Biotheus and BioNTech Enters the License on PD-L1/VEGF-A BsAbs PM8002 (BNT327)

Announced Date: 2023-11-06 (November 6, 2023) Asset Name: PM8002 (BNT327) Licensor (Seller): Zhuhai Biotheus Inc (China) … [China BD 2023] Biotheus and BioNTech Enters the License on PD-L1/VEGF-A BsAbs PM8002 (BNT327)Read more

by admin•November 7, 2023September 9, 2025•1
Posted in
  • China License Out

[China BD 2023] MediLink and BioNTech enters a 1 billion USD License on HER3 ADC YL202 (BNT326)

Announced Date: 2023-10-12 (October 12, 2023) Asset Name: YL202 (BNT326) Licensor (Seller): MediLink Therapeutics (China) Licensee … [China BD 2023] MediLink and BioNTech enters a 1 billion USD License on HER3 ADC YL202 (BNT326)Read more

by admin•October 13, 2023September 10, 2025•1
Posted in
  • China License Out

[China BD Deal 2023] Hansoh and GSK enters a 1.57 billion USD license on B7-H4 ADC HS-20089

Announced Date: 2023-10-20 (October 20, 2023) Asset Name: HS-20089 Licensor: Hansoh Pharma  (Hansoh) (China) Licensee (Buyer): … [China BD Deal 2023] Hansoh and GSK enters a 1.57 billion USD license on B7-H4 ADC HS-20089Read more

by admin•September 21, 2023September 1, 2025•0
Posted in
  • China License Out

[China BD 2023] Insilico Medicine and Exelixis enters a 800 million USD license on USP1 Inhibitor ISM3091

Announced Date: 2023-09-12 (September 12, 2023) Asset Name: ISM3091 Licensor: InSilico Medicine (China) Licensee (Buyer): Exelixis, … [China BD 2023] Insilico Medicine and Exelixis enters a 800 million USD license on USP1 Inhibitor ISM3091Read more

by admin•September 13, 2023September 7, 2025•0
Posted in
  • China License Out

[China BD 2023] LaNova and AstraZeneca Enters a 600 million USD License on GPRC5D ADC LM-305

Announced Date: 2023-05-12 (May 12, 2023) Asset Name: LM-299 Licensor (Seller): LaNova Medicines (LaNova) (China) Licensee … [China BD 2023] LaNova and AstraZeneca Enters a 600 million USD License on GPRC5D ADC LM-305Read more

by admin•May 13, 2023September 9, 2025•0

Posts pagination

Previous 1 … 7 8 9 10 Next

Recent Posts

  • [China BD 2025] TransThera and Neurocrine Enters a 882 USD Million License on NLRP3 Inhibitor Program
  • China NMPA Approved New Drugs (Biological Products) ADC
  • [China BD 2025] Minwei Biotech (Lepu) and Sidera Bio Enters a 1 Billion USD License for GLP-1/GIP/FGF21 Agonist Peptides MWN105
  • [China BD 2025] Qyuns Therapeutics and Roche Entered a 107 Million USD License for TSLP/IL-33 Bispecific Antibody QX031N
  • [China BD 2025] Innovent Biologics and Takada enters 11.4 Billion USD License and Collaboration Agreement on  Three Oncology Assets, IBI363 (PD-1/IL-2α-bias), IBI343 (CLDN18.2 ADC) and IBI3001 (EGFR/B7H3 ADC)

Recent Comments

  1. [China BD 2024] [China Biotech M&A] Biotheus and BioNTech Enters an Acquisition on PD-L1/VEGF-A BsAbs PM8002 (BNT327) – CninMed – China Innovative Drugs Update on [China BD 2023] Biotheus and BioNTech Enters the License on PD-L1/VEGF-A BsAbs PM8002 (BNT327)
  2. [Technology Collaboration] MediLink and BioNTech Expand the Collaboration on several ADC products – CninMed – China Innovative Drugs Update on [China BD 2023] MediLink and BioNTech enters a 1 billion USD License on HER3 ADC YL202 (BNT326)
  3. [China Original Asset] BioNTech and BMS enters a 11.1 billion USD Collaboration on PD-L1xVEGF-A BsAbs BNT327 (PM8002 from Biotheus) – CninMed – China Innovative Drugs Update on [China BD 2024] [China Biotech M&A] Biotheus and BioNTech Enters an Acquisition on PD-L1/VEGF-A BsAbs PM8002 (BNT327)
  4. admin on [China BD Deal] TUL and Novo Nordisk enters a 2 billion USD license for UBT251, a GLP-1/GIP/glucagon triple receptor agonist

Categories

  • China Biotech M&A
  • China FIC Drug
  • China License Out
  • China New Drug
  • China NewCo
  • China Original Asset
  • China Tech Corp
Copyright © 2025 CninMed - China Innovative Drugs Update.
Powered by WordPress and HybridMag.
  • Contact Us